Trial Profile

A phase 1 study of IDE196 in combination with crizotinib in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including metastatic uveal melanoma (MUM), skin melanoma, lung cancer and colorectal cancer.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Crizotinib (Primary) ; Darovasertib (Primary)
Indications Colorectal cancer; Lung cancer; Malignant melanoma; Solid tumours; Uveal melanoma
Focus Adverse reactions
Sponsors IDEAYA Biosciences

10 Jan 2022 According to an IDEAYA Biosciences media release, company is targeting update of clinical data and regulatory guidance on potential registrational clinical trial in first half 2022
05 Jan 2021 According to an IDEAYA Biosciences media release, first patient has been dosed in this study.
05 Jan 2021 Status changed from planning to recruiting, according to an IDEAYA Biosciences media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com